Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27568268 | 0.96 | SIGMAR1 (0.39) | SIGMAR1WDR5 | |
| SCHEMBL15825704 | 0.91 | — | — | |
| SCHEMBL31566399 | 0.82 | HCAR1 (0.32) | — | |
| SCHEMBL28752475 | 0.82 | SMYD3 (0.34) | SIGMAR1 | |
| SCHEMBL28752476 | 0.82 | SMYD3 (0.34) | SIGMAR1 | |
| SCHEMBL5801953 | 0.82 | MEN1 (0.39) | — | |
| SCHEMBL5800638 | 0.81 | GAA (0.40) | SIGMAR1 | |
| SCHEMBL5013702 | 0.81 | MPO (0.41) | — | |
| SCHEMBL19471825 | 0.81 | TLR8 (0.36) | SIGMAR1 | |
| SCHEMBL28757061 | 0.81 | SIGMAR1 (0.36) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2023224894-A9 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | SIGMAR1 4452/4885WDR5 1174/4885AADAT 1209/4885 |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | SIGMAR1 1646/4885WDR5 1426/4885AADAT 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.